Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

61 Multiple Sclerosis Trials near Michigan

Power is an online platform that helps thousands of Multiple Sclerosis patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Frexalimab for Multiple Sclerosis

Milwaukee, Wisconsin
This trial is testing a new drug called SAR441344 to see if it can reduce the number of new active brain lesions in patients. The study will also check how well the drug works overall, its safety, and how it behaves in the body. Patients will participate for several years, including screening, treatment, and follow-up periods.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55

129 Participants Needed

Orelabrutinib for Multiple Sclerosis

Northbrook, Illinois
This trial is testing Orelabrutinib, a medication for people with Relapsing-Remitting Multiple Sclerosis. It aims to reduce immune cell activity that causes attacks on the nervous system, potentially lowering the frequency and severity of relapses.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:18 - 55

160 Participants Needed

Physical Therapy for Multiple Sclerosis

Ann Arbor, Michigan
Physical activity and exercise help manage symptoms like fatigue in people living with multiple sclerosis (MS). Despite research supporting physical activity participation, people with MS are often insufficiently active to reach health benefits. Promotional efforts that are sustainable within the United States healthcare system are needed. This project is a pilot randomized controlled trial examining the feasibility of a consultative physical therapy intervention for increasing physical activity engagement.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

40 Participants Needed

Why Other Patients Applied

I've been battling multiple sclerosis for 28 years. I've tried three medications. I keep my dosing stable, but I'm just tired of managing. I want to take control of my situation.

KE
Multiple Sclerosis PatientAge: 43

I am 42 yrs old with 2 little kids, work as a nurse, tried several drugs, most made me feel awful. I want my quality of life. I don’t want to have to take something daily/monthly. I don’t like the side effects of many drugs. I'm excited to be considered as a candidate for one of these trials.

KT
Multiple Sclerosis PatientAge: 44

I've tried 2 MS drugs but I am getting worse. I am having trouble walking long distances or for more than 30 minutes. I need to find a new medication. My doctor and I discussed some of the options in trials and I'm ready to dive in to learn more.

OL
Multiple Sclerosis PatientAge: 57

I've been taking Kesimpta for a couple years now and seem to be having more flare ups. I'm only 43. I have 5 kids and feel like I'm missing my life. Sleeping my life away. I'm ready to try ANYTHING for a chance at living life again.

XJ
Multiple Sclerosis PatientAge: 43

I've been using natural supplements and would like to find something more effective. My former PCP was hesitant to prescribe modafanil. I'm interested in learning about all options available to me—including the drugs currently under research investigation.

GK
Multiple Sclerosis PatientAge: 50
Match to a Multiple Sclerosis Trial

Exercise Rehabilitation for Multiple Sclerosis

Chicago, Illinois
Approximately 50% of people with multiple sclerosis (MS) use a wheelchair within 30 years of the initial diagnosis. Wheelchair use in MS is often associated with fatigue as a consequence of muscle weakness. Indeed, fatigue, a prevalent consequence of MS, often becomes debilitating and exhausts energetic resources when carrying-out tasks of daily life and/or interacting with the community, as these require ambulatory mobility. This experience of excessive fatigue has its roots in muscle weakness and results in reliance on a wheelchair for mobility, and the dependency on a wheelchair may further reduce muscular strength, particularly of the lower extremities. We propose that wheelchair users with MS can increase muscular strength through a personalized exercise rehabilitation, and this in turn will improve ambulatory performance and possibly reduce fatigue. To date, no research has examined the effects of this specific exercise rehabilitation program (GH method) on physical function and other disease-related outcomes in persons with MS who use wheelchairs as a primary mobility device.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

24 Participants Needed

Acute Intermittent Hypoxia for Multiple Sclerosis

Chicago, Illinois
This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

22 Participants Needed

Physical Activity for Multiple Sclerosis

Chicago, Illinois
The overall objective of the current study is to determine the efficacy of a 16-week remotely delivered lifestyle behavioral intervention compared with a control condition (i.e., waitlist control) in persons newly diagnosed with MS (disease duration ≤ 2 years). Specific Aim 1: To evaluate the changes in self-report and device-measured physical activity after the 16-week remotely delivered physical activity behavior change intervention compared with a control condition (i.e., waitlist control) in persons who have diagnosed with MS within the past two years. The investigators hypothesize that the 16-week behavior change intervention will yield greater improvements in physical activity levels than the control condition immediately after the intervention. Specific Aim 2: To investigate the efficacy of the 16-week, remotely delivered physical activity behavior change intervention compared with the control condition for improvements in fatigue, depression, anxiety, and QoL in persons newly diagnosed with MS. The investigators hypothesize that there will be beneficial effects on the symptoms and QoL outcomes immediately after the physical activity intervention compared with minimal changes in the control condition.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased

52 Participants Needed

Functional Balance Intervention for Multiple Sclerosis

Chicago, Illinois
This project involves two sub-parts: Study 1: Effect of lab-based Functional Balance Intervention (FBI) for physical and cognitive symptoms of Multiple Sclerosis. Study 2: Feasibility of home-based FBI for physical and cognitive symptoms of Multiple Sclerosis. Each study involves a 2-arm, Phase-1, randomized controlled clinical trial to evaluate the effect of FBI on physical, cognitive function, and daily living among people with MS (PwMS). Study 1 is conducted in a lab setting, while Study 2 is conducted at home with additional safety measures. A total of 150 people with multiple sclerosis will be recruited and telephone screened, with an expected enrollment of 120 (60 per phase). After in-person screening, 96 eligible participants (48 per phase) will undergo pre-training assessment and randomization into FBI or Stretching groups. Training sessions will occur twice a week for four months. Anticipating a 15-17% attrition rate, the target sample size is 80 (40 per phase) for completion of the study. Post-training assessments will be conducted after four months to evaluate FBI's impact on physical and cognitive functions. This evidence-based protocol, previously successful with neurological and older adult populations, intends to provide a low-cost, safe, and effective intervention for PwMS in clinical and community settings, including rural areas.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

120 Participants Needed

Intermittent Hypoxia for Multiple Sclerosis

Chicago, Illinois
This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

21 Participants Needed

High-Intensity Gait Training for Multiple Sclerosis

Chicago, Illinois
Nearly 1 million individuals in the United States have multiple sclerosis, which causes fatigue and problems with walking. Fatigue and walking problems are poorly treated, but exercise training, particularly high-intensity walking exercise, may help. This provide insight into whether high-intensity walking exercise can improve fatigue and walking problems in people with multiple sclerosis, which could improve quality of life and reduce economic burden.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21+

20 Participants Needed

Remote Exercise Training for Multiple Sclerosis

Chicago, Illinois
This trial investigates a home-based exercise program for Hispanics/Latinos with multiple sclerosis (MS). The program includes flexibility, aerobic, and resistance exercises guided by experienced coaches. It aims to improve physical function, manage symptoms, and enhance quality of life for this underserved group. The study also examines how factors like income and access to healthcare affect the program's success.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 65

50 Participants Needed

MSCopilot® App for Multiple Sclerosis

Northbrook, Illinois
This trial is testing MSCopilot® Detect, a smartphone app that helps people with Multiple Sclerosis (MS) monitor their condition from home. The app aims to make it easier to track disease progression and improve patient care. It involves 314 MS patients from several countries who will use the app to complete periodic questionnaires and tests. MSCopilot is a software medical device designed for the self-assessment of people with Multiple Sclerosis (PwMS), validated against traditional tests.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:30 - 65

314 Participants Needed

High-Intensity Treadmill Training for Multiple Sclerosis

Milwaukee, Wisconsin
This trial aims to help people with mild to moderate multiple sclerosis walk better by having them exercise intensely and practice balancing on a shaky treadmill. The combination of these activities is expected to improve their walking speed, endurance, and balance.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

150 Participants Needed

Combination Therapies + Lifestyle Modifications for Traumatic Brain Injury

Ann Arbor, Michigan
This trial tests if combining talking therapy, brain exercises, and lifestyle changes can help people with neurocognitive disorders live better lives by improving their thinking, brain function, and daily habits.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased
Age:21 - 65

56 Participants Needed

Exercise Training Program for Multiple Sclerosis

Chicago, Illinois
The proposed project involves a high-quality randomized controlled (RCT) design that examines the effects of a remotely-delivered, racially-tailored exercise training program for immediate and sustained improvement in walking dysfunction, symptoms, and health-related quality of life (HRQOL) among African-Americans with MS residing in rural environments. The primary analysis will test the hypothesis that those who are randomly assigned into the intervention condition (i.e., exercise training) will demonstrate (a) improvements in outcomes from baseline that (b) are sustained over 4-months of follow-up compared with those in the control condition (i.e., stretching).

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

100 Participants Needed

Online Physical Activity Program for Multiple Sclerosis

Chicago, Illinois
We propose a highly-informed, well-designed randomized controlled trial (RCT) that is critical for providing Class I evidence regarding an Internet-delivered physical activity (PA) intervention as a behavioral approach for managing slowed cognitive processing speed (CPS; the most common and perhaps most burdensome MS-related cognitive impairment) and its second learning and memory, symptomatic, and quality of life (QOL) correlates among fully-ambulatory persons with multiple sclerosis (MS) who present with CPS impairment. Such an approach will involve a single-blind, RCT that examines the effects of a remotely-delivered, Internet-based PA intervention compared with an active control condition for yielding immediate and sustained improvements in CPS, learning and memory, symptomatic, and QOL outcomes among persons with mild MS-related ambulatory impairment who demonstrate impaired CPS. The primary outcome is the raw (unadjusted), oral Symbol Digit Modalities Test (SDMT) score as a neuropsychological measure of CPS, and this will be collected remotely via screen-sharing technology. The secondary outcomes include an objective neuropsychological measure of learning and memory (California Verbal Learning Test-II) collected remotely via screen-sharing technology, self-report measures of fatigue (Fatigue Severity Scale), depressive symptoms and anxiety (Hospital Anxiety and Depression Scale), pain (Short-Form, McGill Pain Questionnaire) and QOL (Multiple Sclerosis Impact Scale-29) that will be captured remotely using Qualtrics. The tertiary outcome is accelerometry as an objective, device-based measure of steps/day that will be delivered and returned via pre-paid, pre-addressed envelopes through the United States Postal Service for generating a minimal clinically important difference value that guides the prescription of free-living PA for managing CPS impairment in clinical practice.

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

280 Participants Needed

Backward vs Forward Walking Training for Multiple Sclerosis

Detroit, Michigan
This trial will test if practicing walking backward can help people with multiple sclerosis (MS) improve their balance and reduce their risk of falling. People with MS often have trouble with mobility and thinking, leading to frequent falls. Current methods like forward walking exercises haven't been very effective. The study will compare backward walking to forward walking to see which is better for improving motor function and preventing falls.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

90 Participants Needed

Early Aggressive vs Traditional Therapy for Multiple Sclerosis

Milwaukee, Wisconsin
FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:18 - 60

900 Participants Needed

AIH + NMES for Multiple Sclerosis

Chicago, Illinois
The purpose of this study is to examine how neuromuscular electrical stimulation (NMES), may synergistically enhance corticospinal excitability in people with relapsing form multiple sclerosis (MS). This is an important intermediate step to evaluate the potential of AIH + NMES as a plasticity-priming strategy for more efficacious interventions for persons with MS. This study will measure ankle torque generation and amplitude of motor evoked potentials (MEPs) using a repeated measures study design in order to better understand the effects of AIH combined with NMES, as compared to only receiving NMES, and only receiving AIH.
No Placebo Group

Trial Details

Trial Status:Not Yet Recruiting
Trial Phase:Unphased

20 Participants Needed

Ofatumumab for Multiple Sclerosis

Milwaukee, Wisconsin
Open-label study to evaluate the effectiveness of treatment with ofatumumab in subjects transitioning from any fumarate-based RMS approved therapy or fingolimod due to breakthrough disease.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 60

562 Participants Needed

Exercise Training for Older Adults With Multiple Sclerosis

Chicago, Illinois
The overall objective of the proposed randomized controlled (RCT) is to determine the feasibility and efficacy of a 16-week theory-based, remotely-delivered, combined exercise (aerobic and resistance) training intervention for improving cognitive and physical function in older adults (50+ years) with multiple sclerosis (MS) who have mild-to-moderate cognitive and walking impairment. Participants (N=50) will be randomly assigned into exercise training (combined aerobic and resistance exercise) condition or active control (flexibility and stretching) condition. The 16-week intervention will be delivered and monitored remotely within a participant's home/community and supported by Zoom-based chats guided by social cognitive theory (SCT) via a behavioral coach. Participants will receive training materials (e.g., prescriptive manual and exercise equipment), one-on-one coaching, action-planning via calendars, self-monitoring via logs, and SCT-based newsletters. It is hypothesized that the home-based exercise intervention will yield beneficial effects on cognition, mobility, physical activity, and vascular function compared with an active control condition (flexibility and stretching intervention), and these improvements will be sustained during a 16-week follow-up period.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Age:50+

51 Participants Needed

Balance Training for Multiple Sclerosis

Detroit, Michigan
Multiple Sclerosis (MS) is characterized by episodic attacks in which there are sharp declines in physical function. Although neurorehabilitation is the most promising clinical strategy for motor recovery in patients with MS, treatment responsiveness and outcomes are mixed. This is perhaps because each individual with MS has a different capacity to improve with rehabilitation, and this capacity may be based on a variety of baseline factors, such as disease duration, motivation, cognitive status and integrity of underlying brain structures. A better understanding of what "key ingredients" facilitate relearning of motor skills during neurorehabilitation is critically needed. Much of the focus of rehabilitation is on relearning motor skills. The initial stage of learning a motor skills often requires explicit concentration on the details of the movement. As one becomes more proficient in the motor skill, it becomes less attention-demanding and more automatic. Those who can perform motor skills more automatically will be better able to manage the additional demands of a secondary task; thus, capacity for dual-task performance can be used as an index of automaticity. Individuals with MS experience demyelination that impacts brain areas critical for motor learning. However, the specific clinical and pathological variables that facilitate capacity for motor learning in people with MS have not been identified. Identification of such variables could be leveraged to determine a patient's capacity to benefit from neurorehabilitation at the outset and potentially to maximize motor learning during rehabilitation for people with MS. Thus, there is an urgent need to determine the key ingredients most strongly associated with successful relearning of motor skills in MS patients. Our long-term goal is to develop individualized rehabilitation for persons with MS. Our overall objective in this application is to identify clinical and pathological variables associated with successful relearning of motor skills. Our central hypothesis, based on preliminary data, is that the ability to learn to make new movements automatically occurs over a dynamic range and is a function of available cognitive processing speed and the integrity of corticospinal tract and superior cerebellar peduncles. We will test these hypotheses by recruiting 146 individuals with relapsing-remitting MS to participate in a mechanistic trial not designed to be a therapeutic intervention. Participants will complete baseline testing (including neuroimaging, cognitive testing and dual-task performance) followed by 4 consecutive days of training on a challenging balance task. After a 2-day washout period, participants will return for post-testing (including dual-task performance on a dual-balance and working memory task). The rationale for the proposed research is that identification of key ingredients associated with the capacity for motor skill acquisition would allow for more targeted rehabilitation programming, thereby improving patient outcomes and reducing health care expenses. At the completion of the proposed research, we expect to understand more about the capacity for individuals with MS to improve with motor skill training, and some of the key ingredients that help predict successful shift toward task automaticity, one critical component of successful neurorehabilitation. The results of this proposal will facilitate the development of predictors of motor recovery, needed to improve rehabilitation outcomes for individuals with MS and other neurodegenerative diseases.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Age:18 - 65

150 Participants Needed

IMU-838 for Progressive Multiple Sclerosis

Northbrook, Illinois
This trial is testing a new medication called IMU-838 to help adults with Progressive Multiple Sclerosis. The medication aims to reduce inflammation and slow down the worsening of the disease. The study will check if the medication is safe and effective over a long period.

Trial Details

Trial Status:Active Not Recruiting
Age:18 - 65

450 Participants Needed

IMU-838 for Multiple Sclerosis

Northbrook, Illinois
This trial is testing IMU-838, a medication for adults with relapsing multiple sclerosis. The drug aims to reduce immune system activity to prevent nerve damage and manage symptom flare-ups.
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 55

1050 Participants Needed

Liraglutide for Obesity

Chicago, Illinois
This study is for people who have multiple sclerosis, acute leukemia (in remission), or long-COVID and a Body Mass Index over 27 and may struggle with cognitive issues such as remembering information, concentrating, or making decisions that affect everyday life. By doing this study, researchers hope to learn how liraglutide (Saxenda®), a weight loss drug, affects levels of a certain disease marker in the body called Brain Derived Neurotrophic Factor (BDNF). Participation in this research will last about 21 weeks.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Early Phase 1
Age:18 - 40

30 Participants Needed

Powered KAFO for Mobility Impairments

Chicago, Illinois
This trial is testing a special powered leg brace called the Nomad powered KAFO. It aims to help people who have trouble walking due to injuries. The brace provides extra support and power to make walking easier and safer.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

36 Participants Needed

Exercise Training for Depression in Multiple Sclerosis

Chicago, Illinois
The purpose of this research is to examine the effects of two different exercise training regimens for managing depression and improving other health indicators among persons with multiple sclerosis (MS). The project will enroll persons with MS and major depressive disorder (MDD) between 18 and 64 years of age. The investigators will enroll a total of 146 participants. This is a Phase-II trial that compares the efficacy of an exercise training program (POWER-MS) compared with a stretching program (FLEX-MS) for immediate and sustained reductions in the severity of depression among persons with MS who have MDD.
No Placebo Group

Trial Details

Trial Status:Recruiting
Age:18 - 64

146 Participants Needed

CC-97540 for Multiple Sclerosis

Milwaukee, Wisconsin
This trial is testing a new drug called CC-97540 to see if it is safe and effective for people with relapsing or progressive multiple sclerosis. The goal is to find out if it can help manage symptoms or slow down the disease.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1
Age:18 - 60

120 Participants Needed

Activity Monitoring for Parkinson's Disease and Multiple Sclerosis

Chicago, Illinois
The purpose of this study is to examine physical activity and exercise behaviors in people with Parkinson's Disease and Multiple Sclerosis over the course of 1-year using a cloud-based remote monitoring platform.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Unphased

200 Participants Needed

Nivolumab for Cancer

Chicago, Illinois
This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1

300 Participants Needed

Medical Cannabis for Chronic Pain

Toledo, Ohio
This trial will investigate if medical cannabis can effectively reduce pain and improve quality of life for patients with chronic conditions. The study will gather data through an online questionnaire about patients' use of cannabis and its effects. Medical cannabis interacts with the body's natural system to help manage pain and other symptoms. Medical cannabis has been increasingly studied and used as an alternative treatment for managing chronic pain, with numerous studies supporting its potential benefits.
Stay on current meds
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 2
Age:7+

200000 Participants Needed

123

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do Multiple Sclerosis clinical trials in Michigan pay?
Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.
How do Multiple Sclerosis clinical trials in Michigan work?
After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Multiple Sclerosis trials in Michigan 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Michigan for Multiple Sclerosis is 12 months.
How do I participate in a study as a "healthy volunteer"?
Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Michigan several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.
What does the "phase" of a clinical trial mean?
The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.
Do I need to be insured to participate in a Multiple Sclerosis medical study in Michigan ?
Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.
What are the newest Multiple Sclerosis clinical trials in Michigan ?
Most recently, we added Ozanimod vs Fingolimod for Multiple Sclerosis, Ofatumumab for Multiple Sclerosis and Physical Therapy for Multiple Sclerosis to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials

Anxiety Clinical Trials

Schizophrenia Clinical Trials

ADHD Clinical Trials

Bipolar Disorder Clinical Trials

Multiple Sclerosis Clinical Trials

Autism Clinical Trials

Treatment Resistant Depression Clinical Trials

Borderline Personality Disorder Clinical Trials

Social Anxiety Disorder Clinical Trials

Parkinson's Disease Clinical Trials

Alzheimer's Disease Clinical Trials

By Location

Clinical Trials in California

Clinical Trials in Florida

Clinical Trials in Texas

Clinical Trials in New York

Clinical Trials in Ohio

Clinical Trials in Illinois

Clinical Trials in Pennsylvania

Clinical Trials in Michigan

Clinical Trials in North Carolina

Clinical Trials in Massachusetts

Clinical Trials in Missouri

Clinical Trials in Minnesota

Other People Viewed

By Subject

46 Colorectal Cancer Trials near Kansas City, MO

Top Retinitis Pigmentosa Clinical Trials near Long Beach, CA

143 Clinical Trials near Springfield, IL

Top Lynch Syndrome Clinical Trials

Top Back Pain Clinical Trials

143 Clinical Trials near Elizabethtown, KY

124 Clinical Trials near Hanover, PA

Top Acute Myeloid Leukemia Clinical Trials

Top Alzheimer's Disease Clinical Trials near Denver, CO

182 Clinical Trials near Calabash, NC

Top Thrombocytopenia Clinical Trials

15 Depression Trials near Las Vegas, NV

By Trial

Pre-op Radiation Therapy for Mesothelioma

Care Ecosystem for Dementia

RFPM + SmartIntake App Validation for Caloric Intake

MRI Monitoring for Oral Cancer

VentriGel for Hypoplastic Left Heart Syndrome

Behavioral Skills Intervention for Autism Spectrum Disorder

A Study to Assess Safety, Tolerability, and Pharmacokinetics of AZD0186

Daxdilimab for Inflammatory Myositis

Ruxolitinib for Precancerous Breast Conditions

Mobile Health Technology for Colorectal Cancer Recovery

mGlide Mobile Health Intervention for High Blood Pressure

Immunotherapy + Chemotherapy for Small Cell Lung Cancer

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security